Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) is a multinational pharmaceutical company that specializes in developing, manufacturing, and marketing prescription drugs and biologic products. The company has a diverse portfolio of products, including cancer and cardiovascular disease treatments. BMS is headquartered in New York City and operates globally, with a strong presence in both developed and emerging markets.
Company Info
US1101221083
110122108
Jan 1, 1972
Highlights
$94.53B
$2.68
17.33
2.26
$47.64B
$31.43B
$16.18B
$37.77 - $62.65
$57.20
1.48%
2.19
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Bristol-Myers Squibb Company (BMY) returned -16.07% year-to-date (YTD) and 8.44% over the past 12 months. Over the past 10 years, BMY returned -0.52% annually, underperforming the S&P 500 benchmark at 10.35%.
BMY
-16.07%
-8.40%
-12.32%
8.44%
-2.52%
-0.52%
^GSPC (Benchmark)
-3.77%
5.53%
-5.60%
8.37%
14.61%
10.35%
Monthly Returns
The table below presents the monthly returns of BMY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.38% | 1.14% | 2.30% | -16.80% | -7.47% | -16.07% | |||||||
| 2024 | -3.65% | 3.85% | 6.86% | -18.03% | -6.49% | 1.07% | 16.26% | 5.03% | 3.58% | 9.00% | 6.19% | -4.49% | 15.81% |
| 2023 | 1.77% | -5.08% | 0.51% | -2.87% | -3.49% | -0.76% | -1.89% | -0.87% | -5.86% | -10.32% | -4.17% | 3.91% | -26.14% |
| 2022 | 4.99% | 5.83% | 7.13% | 3.07% | 0.24% | 2.76% | -4.18% | -8.63% | 5.46% | 9.80% | 3.63% | -10.38% | 18.98% |
| 2021 | -0.97% | -0.16% | 3.74% | -1.12% | 5.29% | 1.67% | 2.32% | -1.49% | -10.78% | -1.30% | -8.17% | 16.26% | 2.88% |
| 2020 | -1.24% | -6.18% | -5.62% | 10.00% | -1.79% | -1.54% | 0.52% | 6.03% | -3.07% | -2.32% | 6.76% | 0.20% | 0.41% |
| 2019 | -4.27% | 4.64% | -7.65% | -1.82% | -2.28% | -0.04% | -1.20% | 8.24% | 5.49% | 14.08% | -0.75% | 12.73% | 27.74% |
| 2018 | 2.82% | 5.75% | -4.46% | -17.05% | 0.94% | 5.17% | 6.93% | 3.06% | 2.53% | -18.07% | 5.78% | -2.77% | -12.90% |
| 2017 | -15.32% | 15.36% | -4.11% | 3.82% | -3.75% | 3.28% | 2.83% | 6.29% | 5.39% | -2.68% | 2.48% | -3.02% | 7.71% |
| 2016 | -9.64% | -0.37% | 3.76% | 12.99% | -0.67% | 3.12% | 1.71% | -23.29% | -6.05% | -4.93% | 10.86% | 3.54% | -13.49% |
| 2015 | 2.10% | 1.08% | 5.88% | -0.62% | 1.37% | 3.00% | -0.80% | -9.40% | 0.17% | 11.40% | 1.61% | 3.22% | 19.26% |
| 2014 | -5.98% | 7.60% | -3.38% | -2.91% | -0.70% | -2.47% | 5.13% | 0.06% | 1.05% | 14.50% | 1.48% | 0.59% | 14.18% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BMY is 62, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Bristol-Myers Squibb Company provided a 5.25% dividend yield over the last twelve months, with an annual payout of $2.44 per share. The company has been increasing its dividends for 3 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $2.44 | $2.40 | $2.28 | $2.16 | $1.47 | $2.29 | $1.64 | $1.60 | $1.56 | $1.14 | $1.49 | $1.45 |
Dividend yield | 5.25% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Monthly Dividends
The table displays the monthly dividend distributions for Bristol-Myers Squibb Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.62 | $0.00 | $0.00 | $0.62 | $0.00 | $1.24 | |||||||
| 2024 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $0.60 | $0.00 | $0.00 | $2.40 |
| 2023 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $2.28 |
| 2022 | $0.54 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $2.16 |
| 2021 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.00 | $0.49 | $0.00 | $0.49 | $0.00 | $0.00 | $0.00 | $1.47 |
| 2020 | $0.45 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.45 | $0.00 | $0.49 | $2.29 |
| 2019 | $0.41 | $0.00 | $0.00 | $0.41 | $0.00 | $0.00 | $0.41 | $0.00 | $0.00 | $0.41 | $0.00 | $0.00 | $1.64 |
| 2018 | $0.40 | $0.00 | $0.00 | $0.40 | $0.00 | $0.00 | $0.40 | $0.00 | $0.00 | $0.40 | $0.00 | $0.00 | $1.60 |
| 2017 | $0.39 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $1.56 |
| 2016 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $1.14 |
| 2015 | $0.00 | $0.00 | $0.00 | $0.37 | $0.00 | $0.00 | $0.37 | $0.00 | $0.37 | $0.00 | $0.00 | $0.38 | $1.49 |
| 2014 | $0.36 | $0.00 | $0.00 | $0.36 | $0.00 | $0.00 | $0.36 | $0.00 | $0.37 | $1.45 |
Dividend Yield & Payout
Dividend Yield
Bristol-Myers Squibb Company has a dividend yield of 5.25%, which is quite average when compared to the overall market.
Payout Ratio
Bristol-Myers Squibb Company has a payout ratio of 33.24%, which is quite average when compared to the overall market. This suggests that Bristol-Myers Squibb Company strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bristol-Myers Squibb Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bristol-Myers Squibb Company was 70.62%, occurring on Jul 24, 2002. Recovery took 2721 trading sessions.
The current Bristol-Myers Squibb Company drawdown is 36.34%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -70.62% | Oct 29, 1999 | 685 | Jul 24, 2002 | 2721 | May 15, 2013 | 3406 |
| -53.72% | Aug 11, 1972 | 538 | Oct 1, 1974 | 184 | Jun 24, 1975 | 722 |
| -47.67% | Dec 5, 2022 | 396 | Jul 3, 2024 | — | — | — |
| -39.3% | Jul 15, 2016 | 759 | Jul 22, 2019 | 462 | May 20, 2021 | 1221 |
| -38.26% | Jan 10, 1992 | 403 | Aug 12, 1993 | 541 | Oct 3, 1995 | 944 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bristol-Myers Squibb Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Bristol-Myers Squibb Company, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 17.6% positive surprise.
Valuation
The Valuation section provides an overview of how Bristol-Myers Squibb Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BMY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/E ratio of 17.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BMY compared to other companies in the Drug Manufacturers - General industry. BMY currently has a PEG ratio of 2.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BMY relative to other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/S ratio of 2.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BMY in comparison with other companies in the Drug Manufacturers - General industry. Currently, BMY has a P/B value of 5.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |